Gelteq (GELS)
Customizable ingestible gels for partner-branded health and animal-health products.
Something off on this page? Send us feedback.
Formulates customizable ingestible gels for partner-branded pharmaceutical, consumer-health and animal-health products, earning product revenue when manufactured gels are delivered. Its small, collaboration-based model relies on contract manufacturers, licensees and distributors while drug candidates remain subject to clinical and regulatory validation.
Develops customizable ingestible gels for pharmaceutical, consumer-health and animal-health partners. Its matrix can be formulated to mask taste, support set dosing, alter viscosity and release characteristics, and carry pharmaceuticals, nutraceuticals, proteins, vitamins, minerals and plant compounds. Offerings span pet gels, pharmaceutical and over-the-counter gels, and nutraceutical and sports-nutrition gels, including the SportsGel brand.
Generates product revenue when partner-branded, white-label or customized gels are manufactured and delivered. Manufacturing, sales and distribution rely on third parties, while regulated human and veterinary drug programs require clinical results and regulatory approval. Commercial activity is concentrated in the United States, Australia and China/East Asia; the company operates as a single development-and-testing segment.
Company facts
No analyst consensus on record.
Not reported.
Balance sheet, Dec 31, 2025Cash & short-term investments $6.6K · Total debt $3.6M · Total assets $14.3M · Shareholders' equity $10.1M
- Revenue
- $63.5K
- Operating income
- −$1.3M
- Net income
- −$1.3M
Reported in AUD, converted at the latest exchange rate
No dividends on record.
| Insiders | 16.29% | 1.50M shares | |
|---|---|---|---|
| 3 holders · as of Mar 18, 2026 | |||
| Other | 83.71% | 7.69M shares | |
| remainder | |||
9.18M company shares as of Sep 2, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nathan J. GivoniInsiderofficer: Chief Executive Officer | 7.16% | 657,087 | filed Mar 18, 2026 |
Bradley Glenn KarpInsiderofficer: Head of Sales and Marketing | 5.45% | 500,000 | filed Mar 18, 2026 |
Simon H. SzewachInsiderdirector | 3.68% | 338,197 | filed Mar 18, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Lexaria Bioscience
Oral drug-delivery platform rival for pharma and consumer licensees.
- Rani
Oral-biologics platform rival for injection-replacement partnerships.
- Lifeward
Successor owner of the filing-named POD oral protein platform.
- Entera Bio
Oral peptide platform rival in metabolic and endocrine drug programs.
- Nutriband
Transdermal drug-delivery alternative for pharmaceutical development partners.
- Insulet
Commercial insulin-delivery alternative to oral diabetes formulations.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Gelteq | $0.5560 | −2.64% | $5.2M | — | — | — | — |
| Lexaria Bioscience | $3.34 | −2.34% | $5.7M | — | — | 29.2 | −88.5% |
| Rani | $0.7869 | −0.32% | $51.6M | — | — | 10.6 | — |
| Lifeward | $7.18 | +2.57% | $11.3M | — | — | 0.5 | +15.7% |
| Entera Bio | $2.98 | +0.68% | $145.9M | — | — | — | — |
| Nutriband | $6.93 | −10.78% | $94.5M | — | — | 58.4 | −29.7% |
| Insulet | $139.58 | −0.68% | $9.73B | 26.3 | 20.3 | 3.2 | +23.5% |
| Median | 26.3 | 20.3 | 10.6 | −7.0% |